MedTrace Logo

The Effect of Topical Rho-kinase Inhibitors on Corneas of Patients With Fuchs Endothelial Corneal Dystrophy

NCT06969586 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2025-05-14

No results posted yet for this study

Summary

The goal of this study is to learn if topical ROCK inhibitors protect endothelial corneal cells in patients with glaucoma and Fuchs endothelial corneal dystrophy after cataract surgery. The main question it aims to answer is: do topical ROCK inhibitors decrease the loss of corneal endothelial cells after cataract surgery? Researchers will compare topical ROCK inhibitor to a placebo (a look-alike substance that contains no drug)

Participants will:

Take topical ROCK inhibitor or a placebo every day for 4 weeks after cataract surgery and visit the clinic for checkups and tests.

Conditions

  • Fuchs Endothelial Corneal Dystrophy
  • Cataract
  • Glaucoma

Interventions

DRUG

Netarsudil 0.02% Ophthalmic Solution

Topical Netarsudil 0.02% 1x daily for 30 days postoperatively

DRUG

artificial tear substitute

Topical artificial tear substitute 1x daily for 30 days postoperatively.

Sponsors & Collaborators

  • University Hospital Dubrava

    lead OTHER

Principal Investigators

  • Josip Pavan, prof.dr.sc. · University Hospital Dubrava

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2026-04-01
Completion
2026-10-01
FDA Drug
Yes

Countries

  • Croatia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06969586 on ClinicalTrials.gov